• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

The o2h human health SEIS fund

Investing in the UK's early-stage SEIS biotech companies specializing in novel drug discovery and enabling services, tools and AI tech.
Request Prospectus
featured in
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
highlights
  • o2h Ventures' Seed Enteprise Investment Scheme (SEIS) focuses on investing in early-stage biotech, driving impactful research in areas like cancer, depression, diseases of the ear and eye, psoriasis, idiopathic pulmonary fibrosis, anti-aging, infectious diseases, etc.
  • Our SEIS fund offers a diverse portfolio with capital growth opportunities and various SEIS tax reliefs, making it an attractive tax-efficeint investment tool.
  • As first investors in approximately 50% of our EIS and SEIS portfolio, and with around 40% being university spinouts, we are committed to nurturing promising and impactful research from their inception.
  • With over 20 years of active experience in biotech investing in the UK, the o2h Ventures team brings a wealth of knowledge and thorough due-diligence. Our extensive industry experience and syndicate partners help us provide necessary real-time support to our portfolio.
Sunil Shah, CEO - o2h Ventures
fund overview
Minimum Investment
10K
Target Return
IRR 20%
Fund StatusOpen, Closing on 31st January, 2025
Fund SizeTarget £10m
Current AUM£ 1.1m
Manager AUM£ 8.05 million
Minimum Subscription£ 10,000
Maximum Subscription£ 200,000
Expected Exit3-7 years
Founder's InvestmentMinimum 10% of every investment
Income Tax ReliefUp to 50% of money invested*
Other ReliefsInheritance Tax Relief, Capital Gains Tax Relief, Loss Relief and others
Contact Request Prospectus

SEIS tax relief is very attractive for UK tax payers

You invest £50k

SEIS gives you £25k tax relief from HMRC

SEIS gives you £25k tax relief from HMRC

IF COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £25k income tax relief

- £10k performance incentive

= £65k net profit

IF VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £25k income tax relief

- £0 performance incentive

= £25k net profit

IF COMPANY FAILS

Investment now worth £0

£50k loss

+ £25k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £9,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

*Tax relief depends on an individual’s circumstances and may change in the future.
why o2h ventures?
+History in grassroots science

We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.

+Evaluation

Since its inception, the o2h group has developed a rigorous process to evaluate its deal flow, particularly regards seed investments. Opportunities come from a wide range of sources, as a result of the o2h group’s extensive network of contacts.

+Access to scientific talents

The team have developed access to some of the most interesting scientific ideas and talent in the UK, achieving a clearly differentiated position through its live working relationships, fostered over many years, working as a discovery services company. This potentially fives o2h ventures earlier access than competitor to some of the most promising companies.

+Business model

The business model identified by o2h ventures gives it an edge both in terms of access to opportunities as well as an understanding of the support they require post investment in terms of incubation. By combining access and incubation we are providing a unique opportunity, reducing investment risk by being deeply involved and the team believe that this will increase Fund’s prospects of making successful exits.

fund registered with
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures

our portfolio

portfolio-image

Enedra Therapeutics Ltd

Developing the first personalised medicines that treat heterogeneous cancers, a formidable challenge in oncology

portfolio-image

Sansanima Ltd

Developing in vitro, cell-based assay technologies to replace animal testing.

portfolio-image

Atelerix Ltd

Hypothermic gel-based technology to preserve live cells, tissues and viruses at room temperature

See the entire portfolio

Sorry, no results found with this search

recent news
  • o2h Ventures Backs Enedra Therapeutics, Targeting Complex Cancers 7 May, 2025
  • o2h Ventures Makes a Follow-on Investment in Qkine, the Cambridge-based Specialist in Growth Factor Manufacturing 21 March, 2025
  • o2h Ventures Investment Spotlight – Revolutionising Prostate Cancer Treatment 30 January, 2025

Get the latest updates about o2h ventures funds

    o2h-ventures
    o2h Ventures Limited
    Hauxton House,
    The Mill SciTech Park,
    Mill Lane, Hauxton
    Cambridge
    CB22 5HX
    07341612481
    invest@o2h.com
    about
    • about us
    • team
    • portfolio
    • funds
    insights and news
    • knowledge hub
    • press releases
    • blog
    • event
    • documents
    connect with us
    • linkedin
    • youtube
    • email
    Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
    Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
    o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
    © 2025 o2h ventures
    • Privacy Policy
    • Blog
    • Contact us

    Risk Information

    Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

    What are the key risks?

    1 – You could lose all the money you invest

    • If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

    2 – You are unlikely to be protected if something goes wrong

    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

    3 – You won’t get your money back quickly

    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

    • The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

    • If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

    4 – Don’t put all your eggs in one basket

    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

    5 – The value of your investment can be reduced

    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

    • These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

    If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)